POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Severe Neutropenia (Grade 4 Neutropenia) as a Population Based Predictor for Adverse Clinical Outcome of Chemotherapy Induced Neutropenia
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Impact of Adding Plinabulin to Pegfilgrastim for the Prevention of Chemotherapy Induced Neutropenia on Patient Quality of Life (QoL)
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Prediction of Febrile Neutropenia , Hospitalization Rates, and Infection Rates in Chemotherapy-Induced Neutropenia Patients Treated with the Plinabulin and Pegfilgrastim Combination (Plin+Peg) using a Meta-Analysis -based Tool
Federation of Clinical Immunology Societies (FOCIS) 2021
06.2021
Federation of Clinical Immunology Societies (FOCIS) 2021
Adding Plinabulin (Plin) to Pegfilgrastim (Peg) Reverses the Immune Suppressive Potential of Peg while Offering Superior Prevention of Chemotherapy Induced Neutropenia (CIN) versus Peg Alone
Subgroup Analysis of Non-Squamous EGFR Wild-Type (WT) 2nd/3rdLine NSCLC Patients from the Global Phase 3 Trial DUBLIN-3 (BPI-2358-103) with the Plinabulin/Docetaxel Combination vs. Docetaxel Alone (2022)
10.2022
American Society of Clinical Oncology (ASCO) Annual Meeting (2022)
Subgroup Analysis of Non-Squamous EGFR Wild-Type (WT) 2nd/3rdLine NSCLC Patients from the Global Phase 3 Trial DUBLIN-3 (BPI-2358-103) with the Plinabulin/Docetaxel Combination vs. Docetaxel Alone
American Society of Hematology (ASH) Annual Meeting (2021)
12.2021
American Society of Hematology (ASH) Annual Meeting (2021)
PLINABULIN RAPIDLY (WITHIN 24 HOURS) REVERSES MYELOSUPPRESSION INDUCED BY CHEMOTHERAPY
PUBLICATIONS
Clinical Cancer Research (2010) 16:5892-5899
12.01.2010
Clinical Cancer Research (2010) 16:5892-5899
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Blood 2011
03.2011
Blood
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells
Cancer Chemotherapy and Pharmacology
12.06.2019
Cancer Chemotherapy and Pharmacology
Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies
Chem
11.14.2019
Chem
Structure, Thermodynamics, and Kinetics of Plinabulin Binding to Two Tubulin Isotypes